NKN. I. Khutsishvili

N. I. Khutsishvili

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


N. I. Khutsishvili has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The role of left atrial strain in predicting cardiovascular outcomes in patients with type 2 diabetes and intermediate probability of heart failure with preserved ejection fraction

    by Zh. D. Kobalava, N. I. Khutsishvili, A. F. Safarova, T. M. Timofeeva, V. V. Tolkacheva, V. P. Efimova

    Aim. To assess the prognostic value of left atrial reservoir strain for predicting the risk of major adverse cardiovascular events in patients with type 2 diabetes (T2D) and intermediate probability of heart failure with preserved ejection fraction (HFpEF) over a 1-year follow-up period. Material and methods. A prospective study initially screened 164 patients with T2D (mean age 61±8 years) presenting with dyspnea and preserved left ventricular ejection fraction (≥50%). Using the HFA-PEFF score: HFpEF was considered unlikely with ≤1 point and confirmed with ≥5 points. The final study cohort comprised 58 patients with intermediate HF probability (2-4 points). These patients underwent standard clinical assessment, including laboratory and instrumental tests, as well as diastolic stress echocardiography (DSE) with physical exercise on a horizontal bicycle ergometer. A positive DSE result was defined as either: 1) an increase in E/e’ ratio ≥15 during exercise (2 points), or 2) an increase in E/e’≥15 accompanied by tricuspid regurgitation velocity >3.4 m/s (3 points). Left atrial strain (LAS) was assessed using speckle-tracking echocardiography with focus on reservoir function, with abnormal values defined as ≤18%. Results. According to DSE, 29.3% of patients had a positive result, confirming a diagnosis of heart failure with preserved ejection fraction (HFpEF). This group exhibited significantly lower LAS values both at rest and during exercise. Reduced LAS during exercise was correlated with increased left ventricular filling pressure. Furthermore, LAS demonstrated independent prognostic value in assessing the risk of adverse events. Kaplan-Meier analysis revealed a statistically significant association between LAS ≤18% and the risk of reaching the composite endpoint in the HFpEF group (Log Rank = 14.72; p Conclusion. In patients with type 2 diabetes and intermediate HFpEF probability, reduced left atrial reservoir strain (≤18%) is a significant predictor of adverse cardiovascular events within a 1-year follow-up period.

  • The impact of Mexidol on improving quality of life parameters and functional kidney status as part of complex therapy for cognitive impairments in comorbid patients with microalbuminuria against the background of arterial hypertension and type 2 diabetes mellitus

    by V.V. Tolkacheva, L.V. Karapetyan, L.G. Ezhova, N.I. Khutsishvili, S.A. Galochkin, E.R. Kazakhmedov, Zh.D. Kobalava

    Objective. Evaluation of the effect of Mexidol as part of the complex therapy of cognitive impairment for 10 weeks on cognitive status, quality of life parameters and kidney function in comorbid patients with microalbuminuria on the background of arterial hypertension (AH) and type 2 diabetes mellitus (DM). Methods. The prospective, open randomized trial included 60 comorbid patients (1:1) with hypertension and type 2 diabetes with cognitive impairment< 24 points on the Montreal Cognitive Function Assessment Scale (MoCA) and microalbuminuria (urinary albumin/creatinine >30 mg/g). The average age of the patients was 64.8±10.3 years, 50% were male. 30 patients were included in the standard therapy group with additional administration of Mexidol (200 mg intramuscularly once a day for 14 days, then 125 mg 3 times a day for 8 weeks) and 30 patients in the standard therapy group. Initially and at the end of the study, the effect of therapy on the cognitive status of patients was assessed using the Montreal Cognitive Function Assessment Scale (MOCA), quality of life parameters based on the results of the Minnesota (MLHFQ), Kansas (Kansas City Cardiomyopathy Questionnaire, KCCQ) and the SF-36 questionnaire «Quality of Life Assessment», the severity and dynamics of asthenic syndrome according to the subjective asthenia assessment scale (MFI-20) and the level of anxiety on the Beck scale. Initially, after 14 days and at the end of the study, the functional state of the kidneys was assessed by serum creatinine and cystatin C, the estimated glomerular filtration rate of GFR by creatinine level (eGFRcr), eGFR by cystatin C level (eGFRCCcys) in the blood and the ratio of albumin/creatinine in urine. Results. Patients who received Mexidol in addition to standard therapy showed a significant improvement in cognitive function on the MoCA scale by 20% (p<0.001), an improvement in the quality of life according to the Minnesota questionnaire by 21% (p<0.001), according to the Kansas questionnaire by 12% (p=0.05), a decrease in the severity of asthenic syndrome by 18% (p<0.001) and anxiety levels by 41% (p<0.001), a significant improvement in the functional state of the kidneys in the form of a decrease in albuminuria by 71% (p<0.001), creatinine by 7.3% (p<0.01), cystatin C by 18% (p<0.001), increased eGFRcr by 8.7% (p<0.001), eGFRcys by 11.28% (p<0.001). Conclusion. Mexidol, when added to standard therapy in comorbid patients with microalbuminuria on the background of hypertension and type 2 diabetes, significantly improves cognitive status, quality of life parameters, reduces the severity of asthenic syndrome and anxiety levels, and improves the functional state of the kidneys.

  • Open Access

    Assessing pulmonary congestion in patients hospitalized with decompensated chronic heart failure according to lung ultrasound and remote dielectric sensing (ReDS)

    by Zh. D. Kobalava, A. F. Safarova, V. V. Tolkacheva, O. T. Zorya, F. E. Cabello Montoya, I. S. Nazarov, A. A. Lapshin, I. P. Smirnov, N. I. Khutsishvili, S. A. Galochkin, et al.

    Aim. To conduct a comparative assessment of parameters and dynamics of pulmonary congestion according to lung ultrasound and remote dielectric sensing (ReDS) in patients hospitalized with decompensated chronic heart failure (CHF).Materials and methods. The pilot single-center study included patients hospitalized with decompensated CHF. Lung ultrasound and ReDS were simultaneously performed within 24 hours from the moment of hospitalization and at discharge. Eight-zone lung ultrasound was performed with the calculation of the sum of B-lines. Pulmonary congestion was confirmed with the sum of B-lines ≥ 5. ReDS was performed according to the manufacturer’s protocol. Congestion was confirmed at the value of more than 35%. To determine ReDS interoperator variability, each patient was examined by two operators who were blind to each other’s findings with a 20–30-minute interval.Results. Thirty-five patients were included in the study: 40% (n = 14) men, the average age was 71 (65.5; 78.5) years, the median NT-proBNP was 1,379 (470; 4,277) pg / l. Hydrothorax at admission was observed in 31,4% (n = 11) of patients. The incidence of pulmonary congestion according to lung ultrasound was 57.1% (n = 20): 31.4% (n = 11) of patients had mild congestion, 22.9% (n = 8) – moderate, and 2.9% (n = 1) – severe congestion. ReDS data revealed pulmonary congestion in 62.9% (n = 22) of cases, of which 37,1% (n = 13) of cases were characterized by mild, 22.9% (n = 8) – by moderate, and 2.9% (n = 1) – by severe congestion. A moderate correlation was found between ReDS (%) and lung ultrasound (sum of B-lines) findings at admission (Spearman’s rank correlation coefficient = 0.402; p = 0.017). No correlation between the two methods was found at discharge (p = 0.613). The frequency of agreement between lung ultrasound and ReDS on signs of congestion at admission was 77.1% (p = 0.004) with an average Cohen’s Kappa coefficient (κ = 0.53). The average interoperator variability in ReDS was 9.9%.Conclusion. A moderate correlation was revealed between ReDS (%) and lung ultrasound (sum of B-lines) in detecting pulmonary congestion (Spearman’s rank correlation coefficient = 0.402; p = 0.017). No correlation between the two methods was found at discharge (p = 0.613).

  • Open Access

    Liver damage in patients hospitalized with acute decompensated heart failure, depending on the degree of glucose metabolism disorder

    by V. V. Tolkacheva, M. L. Diane, N. I. Khutsishvili, I. A. Misan, F. E. Cabello Montoya, I. S. Nazarov, I. P. Smirnov, Zh. D. Kobalava

    Aim. To study the frequency of cardiohepatic syndrome and steatosis by the value of controlled attenuation parameter (CAP), fibrosis, and their combination, depending on the degree of glucose metabolism disorder in patients with acute decompensated heart failure (ADHF).Materials and methods. The study included 280 patients (53% men, average age 70.1 ± 10.8 years) with ADHF: 72.5% of patients had a history of arterial hypertension, 60% of patients had coronary heart disease. The HbA1c test was performed in all patients to assess the status of glucose metabolism. The patients were divided into groups depending on the results obtained: at HbA1c values < 5.7%, patients were included in the group without glucose metabolism disorders, at HbA1c 5.7–6.4% – in the prediabetes group, at HbA1c ≥ 6.5% – in the type 2 diabetes group. All patients underwent a standard physical examination at admission and at discharge. Clinical and comprehensive assessments of congestion were performed – NT-proBNP, lung ultrasound, liver fibroscan with CAP, and bioelectrical impedance analysis of body composition.Results. The frequency of glucose metabolism disorders in patients hospitalized with ADHF was 57.5% (n = 161), while prediabetes was detected in 17.1% (n = 48) and type 2 diabetes – in 40.4% (n = 113) of patients. We revealed significantly higher incidence of steatosis by CAP value (69 vs. 42%, p < 0.001), fibrosis (80 vs. 64%, p < 0.001), and their combination (59 vs. 30%, p < 0.001), as well as cardiohepatic syndrome (87 vs. 61%, p < 0.001) in patients with ADHF and glucose metabolism disorders compared to individuals with ADHF without glucose metabolism disorders, respectively. The group of ADHF patients with glucose metabolism disorders and a combination of steatosis / fibrosis was characterized by more pronounced manifestations of metabolic syndrome, impaired kidney and liver function, and more pronounced manifestations (both clinical and laboratory) of congestion.Conclusion. In patients with ADHF with glucose metabolism disorders, liver function test and liver fibroscan with CAP allow for identifying the most severe group of patients with a combination of steatosis/fibrosis and pronounced congestion.

  • Open Access

    Acute myocardial infarction-like event in a young patient with biventricular arrhythmogenic cardiomyopathy

    by Y. V. Stavtseva, E. A. Mershina, T. V. Lobzhanidze, E. I. Bazdireva, N. I. Khutsishvili, Zh. D. Kobalava

    The article describes a clinical case of biventricular arrhythmogenic cardiomyopathy (ACM) presented with myocardial infarction (MI) — like event in a young patient. The patient was hospitalized with suspected acute coronary syndrome and an episode of ventricular tachycardia (VT). Based on increased cardiac troponin, left ventricular systolic dysfunction with wall motion abnormalities, and nonobstructive coronary arteries the initial diagnosis of type 2 MI was made. To verify the etiology behind VT and ventricular structural abnormalities cardiac magnetic resonance imaging (MRI) was performed. Abnormalities of both right and left ventricles demonstrated by MRI and supported by the genetic testing established the diagnosis of biventricular ACM. Since the diagnosis was made, initially diagnosed MI was reassessed in favor of acute myocardial injury as a characteristic of ACM course. ACM should be included into differential diagnosis with MI and acute myocarditis in patients with elevated troponin and nonobstructive coronary arteries.

  • Open Access

    Hydration status in patients hospitalized with acute decompensated heart failure depending on the severity of glucose metabolism disorder

    by V. V. Tolkacheva, M. L. Diane, N. I. Khutsishvili, F. E. Cabello Montoya, I. S. Nazarov, I. P. Smirnov, S. A. Galochkin, Zh. D. Kobalava

    Aim. To study the hydration status according to clinical parameters and laboratory and instrumental research findings at admission and discharge in patients hospitalized with acute decompensated heart failure (ADHF), depending on the severity of glucose metabolism disorder.Materials and methods. The study included 280 patients (53% men, average age 70.1 ± 10.8 years) with ADHF. 72.5% of patients had arterial hypertension in the medical history, 60% of patients had coronary artery disease. In all patients, the level of glycated hemoglobin (HbA1c) was determined to assess the glucose metabolism status. The patients were divided into groups depending on the results obtained: at HbA1c values < 5.7%, patients were included in the group without glucose metabolism disorders, at HbA1c of 5.7–6.4% – in the prediabetes group, at HbA1c ≥ 6.5% – in the type 2 diabetes group. The patients underwent a standard physical examination at admission and at discharge, as well as a clinical and comprehensive assessment of congestion (determination of N-terminal pro B-type natriuretic peptide (NT-proBNP), lung ultrasound, liver Fibroscan testing, including calculation of a controlled attenuation parameter, bioimpedance analysis of the body).Results. The frequency of glucose metabolism disorders in patients hospitalized with ADHF was 57.5% (n = 161), while prediabetes was detected in 17.1% of patients (n = 48) and type 2 diabetes – in 40.4% (n = 113) of cases. Congestion at admission was detected in all patients. A significantly higher frequency of residual (61%) and a lower frequency of subclinical congestion (10%) were revealed in patients with ADHF and type 2 diabetes, compared to patients without glucose metabolism disorders (39% for residual congestion, 27% for subclinical congestion) and prediabetes (40% for residual congestion, 25% for subclinical congestion), respectively. There were no significant differences in the frequency of euvolemia at discharge, depending on the glucose metabolism disorder.Conclusion. Тo assess congestion phenomena at discharge, it is necessary to use clinical, laboratory, and instrumental assessments for patients with ADHF and glucose metabolism disorders. However, in patients with ADHF and prediabetes, it is preferable to focus on the laboratory and instrumental assessment of congestion, while in patients with ADHF and type 2 diabetes, both clinical and laboratory and instrumental assessment of congestion should be performed.


  • Open Access

    Hyperuricemia as a prognostic marker of heart failure readmission and all-cause mortality in patients with acute decompensation of heart failure: a 5-year single center experience

    by D Vinueza Sanchez, V Zambrano Del Valle, F Cabello Montoya, J Munoz Vasquez, J Jimbo Paladines, N Khutsishvili, R Aslanova, E Kotova, V V Tolkacheva, Z H Kobalava

    Funding Acknowledgements: Type of funding sources: None. Introduction: Hyperuricemia is a risk factor for cardiovascular disease. Aim: to determine the prognostic value of asymptomatic hyperuricemia for stratifying the risk of complications in patients with Acute Decompensation of Heart Failure (ADHF) for predicting Heart Failure (HF) readmission and all-cause mortality Material and methods: The study population consisted of 111 ADHF patients (78 men) aged 68 ± 11 years old. Asymptomatic hyperuricemia was defined as a serum UA (uric acid) level > 420 µmol/L (7 mg/dL) in men and >360 µmol/L (6 mg/dL) in women. Study duration was 5 years, the primary end points were HF readmissions and all-cause mortality and combined outcome (HF readmissions + all - cause mortality). Secondary endpoints were uric acid levels, signs of cardiovascular disease and severity of heart failure. ROC curve analysis for predicting primary end points identified the following cut-off of UA: >451 μmol/ L (7,58 mg/dL) (Sensitivity: 70%, Specificity: 56%) Results: Asymptomatic hyperuricemia (HU) was observed in 66, 3% men and 33,7% women ADHF patients. The mean UA level in HU group was 486,1 ± 145 µmol/l (8,17 ± 2,43 mg/dl). Asymptomatic HU group compared with group with normal UA characterized by highest number of patients with HFrEF phenotype [53,8% vs. 27,2%, p 0,05], highest number of patients with dilatation of the right atrium [84,6% vs. 63,6%, p = 0,007], greater dilatation of the right ventricle [3,4 ± 0,64 cm vs 3,1 ± 0,51 cm, p = 0,011], inferior vena cava [2,34 ± 0,39 mm vs 2,1 ± 0,33 mm, p = 0,017] and higher pulmonary pressure [56 mmHg (45 - 68) vs 40 mmHg (34 - 65), p = 0,012] respectively. Cox and Kaplan Meier's analysis showed that uric acid values > 451 µmol/L (7,58 mg/dL) were associated with a higher likelihood of HF readmissions [HR 2,19, 95% CI (1,12–4,23), p=0,02] Log Rank: 0,011 and combined outcome (HF readmissions + all-cause mortality) [HR 1,77, 95% CI (1,00-3,11), p = 0,04] in patients with ADHF. Conclusion: Hyperuricemia can be used as prognostic marker of heart failure readmission and all-cause mortality in patients with ADHF.

  • The effect of mexidol as part of complex therapy on the perception of life in patients with heart failure

    by V.V. Tolkacheva, L.V. Karapetyan, N.I. Khutsishvili, S.A. Galochkin, E.R. Kazakhmedov, Z.D. Kobalava

    Objective. To study the effect of mexidol as part of complex therapy on the perception of life in patients with heart failure (HF). Methods. The open randomized study included 60 comorbid patients with coronary heart disease (CHD) and stable chronic heart failure (CHF) with cognitive impairment (CN) <24 points on the Montreal Cognitive Function Assessment Scale (MoCA). The average age of patients was 73.4±8.6 years, 53% were male, the average left ventricular ejection fraction was 43.5±10.6%. 30 patients were included in the group of standard CHF therapy with additional administration of mexidol (500 mg intravenously once a day for 14 days, then 250 mg 3 times a day for 8 weeks) and 30 patients in the standard therapy group. Initially and at the end of the study, an assessment of the perception of life was carried out. The survey included 4 main areas: (1) the relative importance of disease-related goals, (2) issues related to living with heart failure (HF) and taking HF medications, (3) decision-making process related to the use of HF medications, and (4) awareness and concerns about available HF medications. Results. The main problems associated with living with HF and taking medications for HF, all patients, regardless of the treatment group, initially and after 10 weeks of therapy noted the effectiveness of treatment in reducing the symptoms of HF, in reducing the number of hospitalizations for HF and mortality. Other problems that were most relevant for patients were the presence of shortness of breath, swelling and fatigue, followed by anxiety about the disease, the need to take a large number of medications, the inability to do what they wanted. The patients were least concerned about depression, inability to work, the need for help from relatives, the cost of medications and the struggle with side effects of medications. The beneficial effect of mexidol as part of complex therapy on the patient’s perception of life with HF is shown. Improving the cognitive status of the patient on mexidol treatment contributes to rethinking the main goals of treatment to more global ones — the effectiveness of the drug in reducing mortality, the number of hospitalizations and symptoms of HF, reducing the number of life-limiting factors in the form of edema and shortness of breath, and as a result, increasing the physical activity of the patient. The only limiting factor is the need to take a large number of medications daily and the desire to reduce their number. Conclusion. There is a discrepancy between the priorities of patients and awareness of the optimal drug therapy that has proven its effectiveness. Patients are not familiar with HF therapy, and those who are familiar have concerns about its safety and effectiveness. Long-term sequential therapy with Mexidol when added to standard therapy in patients with chronic heart failure of functional class II-III (according to the NYHA classification) with moderate cognitive status disorders, in addition to a significant improvement in cognitive status and quality of life parameters, favorably affects the patient’s perception of life with heart failure.


  • The effect of Mexidol on the improvement of cognitive status and quality of life parameters in the complex therapy of patients with chronic heart failure II-III functional class

    by V.V. Tolkacheva, L.V. Karapetyan, N.I. Khutsishvili, S.A. Galochkin, E.R. Kazakhmedov, Z.D. Kobalava

    Objective. Evaluation of the effect of mexidol as part of the complex therapy of heart failure for 10 weeks on cognitive status, quality of life parameters, asthenic syndrome and anxiety level in patients with CHF of functional class II-III (according to NYHA classification) Methods. The open randomized study included 60 comorbid patients with ischemic heart disease (CHD) and stable chronic heart failure (CHF) with cognitive impairment (CI) ≤24 points on the Montreal Cognitive Function Assessment Scale (MoCA). The average age of patients was 73.4±8.6 years, 53% were male, the average ejection fraction was 43.5±10.6%. 30 patients were included in the group of standard CHF therapy with additional administration of mexidol (500 mg intravenously once a day for 14 days, then 250 mg 3 times a day for 8 weeks) and 30 patients in the standard therapy group. Initially and at the end of the study, the effect of therapy on the cognitive status of patients was assessed according to the Montreal Cognitive Function Assessment Scale (MoCA), the level of anxiety on the Beck scale, the severity and dynamics of asthenic syndrome on the subjective asthenia assessment scale (MFI-20), the health profile according to the EQ-5D-5L questionnaire and the quality of life parameters according to the results of the assessment of the Minnesota (MLHFQ), Kansas (Kansas City Cardiomyopathy Questionnaire, KCCQ) and the SF36 questionnaire «Quality of life Assessment». Results. Patients who received mexidol in addition to standard therapy showed a significant improvement in cognitive function by 21%, a decrease in anxiety by 38% and the severity of asthenic syndrome by 12%, an improvement in general well-being by 25% according to the EQ-5D-5L questionnaire, as well as the quality of life according to the Minnesota questionnaire by 48%, according to the Kansas questionnaire — by 39%. Conclusion. Mexidol, when added to the standard therapy of patients with CHF of functional class II-III, significantly improves cognitive status, quality of life parameters, reduces the severity of asthenic syndrome and anxiety levels.